Picture EBD Group BioTech Showcase 2020 San Francisco BEU2020 650x76px
Document › Details

Lyomark Pharma GmbH. (8/14/17). "Press Release: Lyomark Pharma GmbH Becomes Majority Shareholder of Lyocontract GmbH".

Product Product contract manufacturing (drugs)
Index term Index term Lyocontract–Lyomark Pharma: investment, 201708 acquisition of majority share in Lyocontract GmbH by Lyomark Pharma GmbH

We are pleased to announce that effective August 1st 2017 Lyomark Pharma GmbH shall become majority shareholder of Lyocontract GmbH. This will expand our combined capabilities and strengthen our overall position in the pharmaceutical industry.

Lyocontract is a state-of-the-art pharmaceutical manufacturing site with the capabilities of producing liquid and freeze-dried parenteral drugs in vials. The site received its manufacturing license in 2012 and has ever since earned the trust of numerous clients in Germany and abroad.

Both companies are privately held and will continue to be managed independently. The transaction will not affect ongoing activities at any of the Lyomark or Lyocontract facilities. Lyomark will continue to provide the current portfolio of products and registrations under Lyomark’s name to its customers. In case of any further questions do not hesitate to contact us.

Record changed: 2018-02-06


Picture [LSA] – The Business Web Portal 650x89px

More documents for Lyomark Pharma (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group BioTech Showcase 2020 San Francisco BEU2020 650x76px

» top